trial

Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients

NCTId NCT00396214
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 83 (actual)
Sponsored by Solvay Pharmaceuticals
Primary completion 2008-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
83 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2007-04
Primary completion
2008-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
BifeprunoxQuetiapine

Sponsors

Solvay PharmaceuticalsLead Sponsor
H. Lundbeck A/SCollaborator
Wyeth is now a wholly owned subsidiary of PfizerCollaborator

Investigators

1
Global Clinical Director SolvayStudy Director

Sites

151 total
Anaheim, United StatesAnaheim, United StatesCerritos, United StatesCosta Mesa, United StatesCulver City, United StatesGlendale, United StatesLong Beach, United StatesLos Angeles, United StatesLos Angeles, United StatesOceanside, United StatesPasadena, United StatesSacramento, United States

Linked catalysts

1
Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Sch — primary completion2008-01

Facts & assertions

4 sourced
Enrollment
83
Phase
PHASE3
Primary Completion Date
2008-01
Status
TERMINATED
relationships
The graph out of here
drug
Bifeprunox
drug
Quetiapine
drug
lead_sponsor
Solvay Pharmaceuticals
company
collaborator
H. Lundbeck A/S
company
Wyeth is now a wholly owned subsidiary of Pfizer
company
indication
Schizophrenia
indication
Schizophrenia
indication
Body Weight Changes
indication
investigator
Global Clinical Director Solvay
person